Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Pheidippides redux: reducing risk for acute cardiac events during marathon running.

Siegel AJ.

Am J Med. 2012 Jul;125(7):630-5. doi: 10.1016/j.amjmed.2011.11.008. Epub 2012 May 18. Review.

PMID:
22608535
2.

Fatal water intoxication and cardiac arrest in runners during marathons: prevention and treatment based on validated clinical paradigms.

Siegel AJ.

Am J Med. 2015 Oct;128(10):1070-5. doi: 10.1016/j.amjmed.2015.03.031. Epub 2015 Apr 22. Review.

PMID:
25910792
3.

Risk for sudden cardiac death associated with marathon running.

Maron BJ, Poliac LC, Roberts WO.

J Am Coll Cardiol. 1996 Aug;28(2):428-31.

4.

Elevated serum cardiac markers in asymptomatic marathon runners after competition: is the myocardium stunned?

Siegel AJ, Sholar M, Yang J, Dhanak E, Lewandrowski KB.

Cardiology. 1997 Nov-Dec;88(6):487-91.

PMID:
9397299
5.

Running: the risk of coronary events : Prevalence and prognostic relevance of coronary atherosclerosis in marathon runners.

Möhlenkamp S, Lehmann N, Breuckmann F, Bröcker-Preuss M, Nassenstein K, Halle M, Budde T, Mann K, Barkhausen J, Heusch G, Jöckel KH, Erbel R; Marathon Study Investigators; Heinz Nixdorf Recall Study Investigators.

Eur Heart J. 2008 Aug;29(15):1903-10. doi: 10.1093/eurheartj/ehn163. Epub 2008 Apr 21.

6.

Marathon run: cardiovascular adaptation and cardiovascular risk.

Predel HG.

Eur Heart J. 2014 Nov 21;35(44):3091-8. doi: 10.1093/eurheartj/eht502. Epub 2014 Jan 9.

7.

Prerace aspirin to protect susceptible runners from cardiac arrest during marathons: is opportunity knocking?

Siegel AJ.

Open Heart. 2015 Jul 2;2(1):e000102. doi: 10.1136/openhrt-2014-000102. eCollection 2015. Review.

8.

Myocardial infarction & sudden death in recreational master marathon runners.

Finn SE, Coviello J.

Nurse Pract. 2011 Feb;36(2):48-53. doi: 10.1097/01.NPR.0000392797.09383.41. Review.

PMID:
21245724
9.

Cardiac risks associated with marathon running.

Day SM, Thompson PD.

Sports Health. 2010 Jul;2(4):301-6.

10.

Sudden cardiac death in marathon runners: can it be prevented?

Corrado D, Thiene G.

Eur Heart J. 2011 Nov;32(21):2591-3. doi: 10.1093/eurheartj/ehr371. No abstract available.

11.

Myocardial function in older male amateur marathon runners: assessment by tissue Doppler echocardiography, speckle tracking, and cardiac biomarkers.

Knebel F, Schimke I, Schroeckh S, Peters H, Eddicks S, Schattke S, Brechtel L, Lock J, Wernecke KD, Dreger H, Grubitz S, Schmidt J, Baumann G, Borges AC.

J Am Soc Echocardiogr. 2009 Jul;22(7):803-9. doi: 10.1016/j.echo.2009.04.009. Epub 2009 Jun 7.

PMID:
19505796
12.

Heart disease in marathon runners: a review.

Noakes TD.

Med Sci Sports Exerc. 1987 Jun;19(3):187-94. Review.

PMID:
3298928
13.

How healthy were the arteries of Phidippides?

Heffernan KS.

Clin Cardiol. 2012 Feb;35(2):65-8. doi: 10.1002/clc.21009. Epub 2011 Nov 28.

14.

Relative risk of sudden cardiac death during marathon running.

Siegel AJ.

Arch Intern Med. 1997 Jun 9;157(11):1269-70. No abstract available.

PMID:
9183244
15.

72-h kinetics of high-sensitive troponin T and inflammatory markers after marathon.

Scherr J, Braun S, Schuster T, Hartmann C, Moehlenkamp S, Wolfarth B, Pressler A, Halle M.

Med Sci Sports Exerc. 2011 Oct;43(10):1819-27. doi: 10.1249/MSS.0b013e31821b12eb.

PMID:
21448080
16.

Cardiac injury markers in non-elite marathon runners.

Jassal DS, Moffat D, Krahn J, Ahmadie R, Fang T, Eschun G, Sharma S.

Int J Sports Med. 2009 Feb;30(2):75-9. doi: 10.1055/s-0028-1104572. Epub 2009 Jan 28.

PMID:
19177312
17.

Some aspects of the acute phase response after a marathon race, and the effects of glutamine supplementation.

Castell LM, Poortmans JR, Leclercq R, Brasseur M, Duchateau J, Newsholme EA.

Eur J Appl Physiol Occup Physiol. 1997;75(1):47-53.

PMID:
9007457
18.

Exercise-induced alterations of signal-averaged electrocardiograms in marathon runners.

Smith GS, Vacek JL, Wilson DB, Hawkins JW, Boyer TA.

Am Heart J. 1989 Dec;118(6):1198-202.

PMID:
2589160
19.

Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.

Jones L, Griffin S, Palmer S, Main C, Orton V, Sculpher M, Sudlow C, Henderson R, Hawkins N, Riemsma R.

Health Technol Assess. 2004 Oct;8(38):iii-iv, 1-196. Review.

20.
Items per page

Supplemental Content

Write to the Help Desk